EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Rising Pharma Holdings Inc., doing business as Rising Pharmaceuticals, is responding to the growing pandemic by furthering lowering prices on essential medicines including Chloroquine Phosphate, USP Tablets and donating Hydroxychloroquine Sulfate, USP Tablets to areas of greatest need.
Rising Pharmaceuticals today announced these initiatives to respond to the growing pandemic in the United States;
- Rising Pharmaceuticals is furthering lowering prices immediately on a key medicine, Chloroquine Phosphate, USP Tablets.
- Rising Pharmaceuticals is donating 1 million doses of Hydroxychloroquine Sulfate, USP Tablets between March and April to areas of greatest need through participating distributors and government agencies.
“It’s through these initiatives and others in development that Rising Pharmaceuticals will continue to respond to the needs of pharmacy and our communities during this crisis.” said Ira Baeringer, Chief Operating Officer. “As it became clear in January that this growing crisis was upon us in the U.S., Rising Pharmaceuticals put these plans in motion to respond. We are committed to expanding our response by identifying additional ways to address our community needs during this pandemic.”
Both Chloroquine Phosphate, USP Tablets and Hydroxychloroquine Sulfate, USP Tablets are primarily indicated for the treatment and prophylaxis of malaria.
Rising Pharma Holdings, Inc., a privately held company, sells generic prescription products and over-the-counter pharmaceutical products under the Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers. At Rising Pharmaceuticals, we continually seek new opportunities to develop our business through strategic partnerships with manufacturers, marketers and distributors under the Rising label.
Rising Pharma Holdings, Inc., doing business as Rising Pharmaceuticals, is a separate and distinct entity, and is in no way affiliated or associated with Rising Pharmaceuticals, Inc. or ACETO Corporation.
